Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Kenvue Sinks After Report RFK Jr. Will Link Tylenol to Autism (Bloomberg) +++ KENVUE Aktie -10,13%

REPLIMUNE Aktie

 >REPLIMUNE Aktienkurs 
5.3 EUR    +6.4%    (Tradegate)
Ask: 5.35 EUR / 1500 Stück
Bid: 5.25 EUR / 1600 Stück
Tagesumsatz: 5270 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
REPLIMUNE Aktie über LYNX handeln
>REPLIMUNE Performance
1 Woche: +4,6%
1 Monat: +2,0%
3 Monate: -41,4%
6 Monate: -56,1%
1 Jahr: -47,2%
laufendes Jahr: -57,6%
>REPLIMUNE Aktie
Name:  REPLIMUNE GR. INC DL-,001
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US76029N1063 / A2JQN1
Symbol/ Ticker:  7R8 (Frankfurt) / REPL (NASDAQ)
Kürzel:  FRA:7R8, ETR:7R8, 7R8:GR, NASDAQ:REPL
Index:  -
Webseite:  https://replimune.com/
Profil:  Replimune Group Inc. is a biotechnology company sp..
>Volltext..
Marktkapitalisierung:  387.92 Mio. EUR
Unternehmenswert:  111.33 Mio. EUR
Umsatz:  -
EBITDA:  -249.8 Mio. EUR
Nettogewinn:  -239.69 Mio. EUR
Gewinn je Aktie:  -2.89 EUR
Schulden:  65.29 Mio. EUR
Liquide Mittel:  83.29 Mio. EUR
Operativer Cashflow:  -188.27 Mio. EUR
Bargeldquote:  6.77
Umsatzwachstum:  -
Gewinnwachstum:  -15.81%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  1 Insider verkaufte innerhalb der letzten 30 Tage Aktien im Wert von 49.157 USD.
Suchwörter:  REPLIMUNE
Letzte Datenerhebung:  05.09.25
>REPLIMUNE Kennzahlen
Aktien/ Unternehmen:
Aktien: 78.06 Mio. St.
Frei handelbar: 82.02%
Rückkaufquote: -34.45%
Mitarbeiter: 479
Umsatz/Mitarb.: -
Analysten:
Analystenrating: Neutral
Kursziel: 19.1%
Bewertung:
KGV: -
KGV lG: -
KUV: -
KBV: 1.37
PEG-Ratio: -1.59
EV/EBITDA: -
Rentabilität:
Bruttomarge: -
Gewinnmarge: -
Operative Marge: -
Managementeffizenz:
Gesamtkaprendite: -55.79%
Eigenkaprendite: -73.44%
>REPLIMUNE Peer Group

Es sind 601 Aktien bekannt.
 
05.09.25 - 14:48
 Levi & Korsinsky Reminds Replimune Group, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 22, 2025 - REPL (PR Newswire)
 
NEW YORK, Sept. 5, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Replimune Group, Inc. ("Replimune Group, Inc." or the "Company") (NASDAQ: REPL) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Replimune Group, Inc.......
04.09.25 - 15:31
 Investor Lawsuit Targets Replimune (REPL) After FDA Deems RP1 Trial Inadequate - Hagens Berman (PR Newswire)
 
SAN FRANCISCO, Sept. 4, 2025 /PRNewswire/ -- A new securities class action lawsuit has been filed against Replimune Group, Inc. (NASDAQ: REPL) and its executives. The lawsuit alleges that the company misled investors by overstating the success of its lead cancer drug, RP1, leading to a......
04.09.25 - 14:48
 September 22, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against REPL (PR Newswire)
 
NEW YORK, Sept. 4, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Replimune Group, Inc. (NASDAQ: REPL). Shareholders who purchased shares of REPL during the class period listed are encouraged to contact the firm regarding possible lead plaintiff......
03.09.25 - 22:21
 Replimune (REPL) Faces Investor Lawsuit After FDA Blocks Cancer Drug Approval - Hagens Berman (PR Newswire)
 
SAN FRANCISCO, Sept. 3, 2025 /PRNewswire/ -- Replimune Group Inc. (NASDAQ: REPL) is under fire from investors following a dramatic regulatory setback that sent its stock into freefall. A newly filed securities class action accuses the biotech firm and its leadership of concealing critical......
03.09.25 - 16:06
 INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - REPL (PR Newswire)
 
NEW YORK, Sept. 3, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Replimune Group, Inc. ("Replimune" or the "Company")(NASDAQ: REPL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or......
03.09.25 - 09:09
 REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with the Schall Law Firm (PR Newswire)
 
LOS ANGELES, Sept. 3, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Replimune Group, Inc. ("Replimune" or "the Company") (NASDAQ: REPL) for violations of §§10(b) and 20(a) of the Securities......
03.09.25 - 03:54
 REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit First Filed by The Rosen Law Firm (PR Newswire)
 
NEW YORK, Sept. 2, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Replimune Group, Inc. (NASDAQ: REPL) between November 22, 2024 and July 21, 2025, both dates inclusive (the "Class Period"), of the important September 22,......
02.09.25 - 21:06
 Replimune gains as FDA to discuss path for rejected skin cancer drug (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
02.09.25 - 16:03
 Class Action Reminder for REPL Investors: Kessler Topaz Meltzer & Check, LLP Reminds Replimune Group, Inc. (REPL) Investors of Securities Fraud Class Action Lawsuit (PR Newswire)
 
RADNOR, Pa., Sept. 2, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Replimune Group, Inc. ("Replimune") (NASDAQ: REPL) on behalf of those who purchased or otherwise......
02.09.25 - 14:48
 Levi & Korsinsky Notifies Replimune Group, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - REPL (PR Newswire)
 
NEW YORK, Sept. 2, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Replimune Group, Inc. ("Replimune Group, Inc." or the "Company") (NASDAQ: REPL) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Replimune Group, Inc.......
02.09.25 - 05:57
 REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with the Schall Law Firm (PR Newswire)
 
LOS ANGELES, Sept. 1, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Replimune Group, Inc. ("Replimune" or "the Company") (NASDAQ: REPL) for violations of §§10(b) and 20(a) of the Securities......
29.08.25 - 17:12
 Faruqi & Faruqi Reminds Replimune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 22, 2025 - REPL (PR Newswire)
 
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Replimune To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Replimune between November 22, 2024 and July 21, 2025......
29.08.25 - 02:24
 REPL Class Action Reminder: Investors with Large Losses Should Contact Robbins LLP for Information About the Pending Lead Plaintiff Deadline in the Replimune Group, Inc. Class Action Lawsuit (PR Newswire)
 
SAN DIEGO, Aug. 28, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Replimune Group, Inc. (NASDAQ: REPL) securities between November 22, 2024 and July 21, 2025. Replimune Group, Inc., a......
28.08.25 - 14:48
 Replimune Group, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - REPL (PR Newswire)
 
NEW YORK, Aug. 28, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Replimune Group, Inc. (NASDAQ: REPL). Shareholders who purchased shares of REPL during the class period listed are encouraged to contact the firm regarding possible lead plaintiff......
28.08.25 - 00:01
 REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit First Filed by The Rosen Law Firm (PR Newswire)
 
NEW YORK, Aug. 27, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Replimune Group, Inc. (NASDAQ: REPL) between November 22, 2024 and July 21, 2025, both dates inclusive (the "Class Period"), of the important September 22,......
26.08.25 - 14:48
 Replimune Group, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before September 22, 2025 to Discuss Your Rights - REPL (PR Newswire)
 
NEW YORK, Aug. 26, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Replimune Group, Inc. ("Replimune Group, Inc." or the "Company") (NASDAQ: REPL) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Replimune Group, Inc.......
26.08.25 - 04:03
 INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - REPL (PR Newswire)
 
NEW YORK, Aug. 25, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Replimune Group, Inc. ("Replimune" or the "Company")(NASDAQ: REPL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or......
25.08.25 - 14:48
 Class Action Filed Against Replimune Group, Inc. (REPL) Seeking Recovery for Investors - Contact The Gross Law Firm (PR Newswire)
 
NEW YORK, Aug. 25, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Replimune Group, Inc. (NASDAQ: REPL). Shareholders who purchased shares of REPL during the class period listed are encouraged to contact the firm regarding possible lead plaintiff......
23.08.25 - 01:03
 REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit First Filed by The Rosen Law Firm (PR Newswire)
 
NEW YORK, Aug. 22, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Replimune Group, Inc. (NASDAQ: REPL) between November 22, 2024 and July 21, 2025, both dates inclusive (the "Class Period"), of the important September 22,......
22.08.25 - 16:03
 INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - REPL (PR Newswire)
 
NEW YORK, Aug. 22, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Replimune Group, Inc. ("Replimune" or the "Company")(NASDAQ: REPL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or......
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Erwachsene sind Kinder mit Schulden. - Franziska Friedl
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!